Immunotherapy with immune checkpoint inhibitor (ICI) monoclonal antibodies has shown to
be an effective therapeutic alternative in several malignant tumors. However, adverse effects …

Objective Immune checkpoint inhibitors have introduced a new and heterogeneous class of
immune-related adverse effects, with the endocrine system being a predominant target for …

Objective Little has been published describing hypophysitis after nivolumab or
pembrolizumab treatment. We aimed to (i) assess the risk of hypophysitis following …

Immune checkpoint inhibitors (ICIs) have become a promising treatment for advanced
malignancies. However, these drugs can induce immune-related adverse events (irAEs) in …

Purpose The aim of our study was to characterize the clinical features of immune‐related
adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) in a real‐world …

Background/Aim: Adrenal insufficiency is one of the adverse events (AEs) associated with
anti-programmed death-1 (PD1) therapy. Delaying diagnoses can lead to serious …

Interventions: Hormone replacements with levothyroxine and acetate cortisone were given
orally. Nivolumab was adjusted to lower dose and longer interval. Outcomes: The patient felt …

Simple Summary This review article is focused on hyponatremia in cancer patients.
Hyponatremia is the most common electrolyte disorder in these patients and there is …

Immune-related adverse events (irAEs) affecting the endocrine glands are among the most
frequent irAEs induced by immune checkpoint inhibitors (ICIs) and include hypopituitarism …

Introduction Immune checkpoint inhibitors are a promising class of anticancer drugs. The
clinical benefits afforded by immune checkpoint inhibitors can be accompanied by immune …